ERBITUX, in combination with radiation therapy, is indicated for the initial treatment of a certain type of locally or regionally advanced head and neck cancer.
ERBITUX, in combination with platinum-based chemotherapy with 5-fluorouracil, is indicated for the initial treatment of patients with a certain type of head and neck cancer whose tumor has returned in the same location or spread to other parts of the body.
ERBITUX is also indicated for use alone to treat patients with a certain type of head and neck cancer whose tumor has returned in the same location or spread to other parts of the body and whose disease has progressed following platinum-based chemotherapy.
ERBITUX is available by prescription only.
Possible serious side effects while taking ERBITUX include allergic reactions and heart attack
Treatment with ERBITUX may cause side effects, including severe allergic reactions. The allergic reactions are rare but may cause death. Tell your doctor or nurse right away if you have trouble breathing, are wheezing or hoarse, or have a tight feeling in your airways. Symptoms of an allergic reaction also include low blood pressure, shock, loss of consciousness, and heart attack. Most of the severe allergic reactions happened with the first dose of ERBITUX. Some people had a severe allergic reaction when receiving a later dose of ERBITUX. Your doctor or nurse should watch you closely while you are receiving ERBITUX. He or she may need to stop giving you ERBITUX if you have an allergic reaction.
In a clinical study, heart attack and/or sudden death occurred in some people with head and neck cancer who received ERBITUX and radiation therapy. No one receiving radiation therapy alone in that study experienced a heart attack and/or sudden death. Tell your doctor if you have a history of heart disease.